Related Experiment Videos
NO synthase inhibition increases aldosterone in humans
James A S Muldowney1, Stephen N Davis, Douglas E Vaughan
1Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-6602, USA.
Hypertension (Dallas, Tex. : 1979)
|September 24, 2004
Summary
Endogenous nitric oxide (NO) plays a role in regulating aldosterone production in humans. Inhibiting NO increased aldosterone levels, an effect reversed by L-arginine and ramipril.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Renal Physiology
Background:
- Nitric oxide (NO) is a critical signaling molecule involved in various physiological processes.
- The precise role of endogenous NO in modulating aldosterone production in humans remains incompletely understood.
- Aldosterone is a key hormone regulating blood pressure and electrolyte balance.
Purpose of the Study:
- To investigate the influence of endogenous nitric oxide (NO) on aldosterone synthesis and secretion in healthy human subjects.
- To determine if NO inhibition affects basal aldosterone levels and if NO precursors or ACE inhibitors can counteract these effects.
Main Methods:
- A randomized, double-blind, placebo-controlled study involving ten healthy subjects.
- Administration of N(G)-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, or vehicle.
- Assessment of aldosterone concentrations, plasma renin activity (PRA), angiotensin II, blood pressure, and heart rate under various conditions, including placebo, L-arginine, ramipril, and combined L-arginine plus ramipril treatment.
Main Results:
- L-NAME infusion significantly increased systolic blood pressure and decreased heart rate across all treatment arms.
- Serum aldosterone levels were significantly elevated during L-NAME infusion compared to vehicle after placebo pretreatment (P=0.045).
- The L-NAME-induced increase in aldosterone was abolished by combined L-arginine and ramipril treatment. No significant effect of L-NAME on PRA or angiotensin II was observed. Significant relationships were found between aldosterone and PRA, and between aldosterone and serum potassium during L-NAME infusion.
Conclusions:
- Endogenous nitric oxide (NO) significantly modulates aldosterone synthesis in humans.
- Inhibition of NO leads to increased aldosterone levels, suggesting a suppressive role for NO in aldosterone production.
- The interplay between NO, renin-angiotensin-aldosterone system (RAAS) components, and potassium warrants further investigation.